Alliance Pharma (GB:APH) has released an update.
Alliance Pharma PLC reported a solid financial performance for 2023 with record sales and a 4% increase in underlying profit before taxation, driven by a strong second half and continued consumer demand, particularly for the Kelo-Cote franchise. Despite non-cash impairments and paused dividends, the company has robust free cash flow and has reduced net debt, positioning itself for growth with investment in marketing and new product development. The company’s strategic focus remains on Consumer Healthcare, with a positive outlook for continued revenue growth and a commitment to sustainability and carbon emission reduction.
For further insights into GB:APH stock, check out TipRanks’ Stock Analysis page.
